The 50 references in paper V. Kliem , Ф. Клим (2007) “ТАКРОЛИМУС ПРИ ТРАНСПЛАНТАЦИИ ПОЧКИ. СООБЩЕНИЕ II // TACROLIMUS IN KIDNEY TRANSPLANTATION” / spz:neicon:nefr:y:2007:i:4:p:18-27

1
Japanese FK-506 Study Group. Japanese study of FK- 506 on kidney transplantation: Results of an early phase II study. Transplant Proc 1991; 23: 3071-3074
(check this in PDF content)
2
Japanese FK-506 Study Group. Japanese study of FK- 506 on kidney transplantation: Results of late phase II study. Transplant Proc 1993; 25: 649-654
(check this in PDF content)
3
Shapiro R, Jordan M, Scantlebury VP et al. FK-506 in clinical kidney transplantation. Transplant Proc 1991; 23: 3056­ 3067
(check this in PDF content)
4
Shapiro R, Jordan ML, Scantlebury VP et al. Randomized trial of FK-506/prednisolone vs FK-506/azathioprine/ prednisone after renal transplantation: Preliminary report. Trans-plant Proc 1993; 25: 669-672
(check this in PDF content)
5
Vincenti F, Laskow DA, Neylan JF et al. One-year follow­ up of an open-label trial of FK-506 for primary kidney transplantation. Transplantation 1996; 61: 1576-1581
(check this in PDF content)
6
Schleibner S, Krauss M, Wagner K et al. FK-506 versus cyclosporine in the prevention of renal allograft rejection - European pilot study: six-week results. Transplant Int 1995; 8: 86-90
(check this in PDF content)
7
Mayer AD, Dmitrewski J, Squifflet JP et al. Multicenter ran-domized trial comparing tacrolimus (FK-506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436-443
(check this in PDF content)
8
Pirsch JD, Miller J, Deierhoi MH et al. for the FK-506 Kidney Transplant Study Group. A comparison of tacrolimus (FK- 506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977-983
(check this in PDF content)
9
Mayer AD. Four-year fol-low-up of the European tacrolimus multicenter renal study. Transplant Proc 1999; 31[Suppl. 7A]: 27S-28S
(check this in PDF content)
10
Jensik SC. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. Transplant Proc 1998; 30: 1216-1218
(check this in PDF content)
11
Hricik DE, O’Toole MA, Schulak JA, Herson J. Steroid- free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993; 4: 1300-1305
(check this in PDF content)
12
Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta­ analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910-1917
(check this in PDF content)
13
Pascual J, Quereda C, Zamora J, Hernandez D. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 2004; 78: 1548­ 1556
(check this in PDF content)
14
Wlodarczyk Z, Walaszewski J, Perner F et al. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients. Ann Transplant 2002; 7: 28-31
(check this in PDF content)
15
Wlodarczyk Z, Walaszewski J, Perner F et al. Steroid withdrawal at three months after kidney transplantation: a comparison of two tacrolimus-based regimens. Transplant Int 2005; 18: 157-162
(check this in PDF content)
16
Vanrenterghem Y, van Hooff JP, Squifflet JP et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant 2005; 5: 87-95
(check this in PDF content)
17
Pascual J, van Hooff JP, Salmela K et al. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. Transplantation 2006; 82: 55-61
(check this in PDF content)
18
Rostaing L, Cantarovich D, Mourad G et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807-814
(check this in PDF content)
19
Vitko S, Klinger M, Salmela K et al. Two corticosteroid- free regimens - tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil - in comparison with a standard triple regimen in renal transplantation: results of the atlas study. Transplantation 2005; 80: 1734-1741
(check this in PDF content)
20
Kramer BK, Kruger B, Mack M et al. Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens. Transplant Proc 2005; 37: 1789-1791
(check this in PDF content)
21
Ekberg H, Tedesco-Silva H, Demirbas A et al. SYMPHONY: Comparing standard immunosuppression to low- dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation. Am J Transplant 2006; 6 [Suppl 2]: 83 (abstract)
(check this in PDF content)
22
Vitko S, Wlodarczyk Z, Kylloenen L et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: Results of a multicenter study. Am J Transplant 2006; 6: 531-538
(check this in PDF content)
23
Dudley CRK for the European Tacrolimus Renal Rejection Study Group. Conversion at first rejection: a prospective trial comparing cyclosporine microemulsion with tacrolimus in renal transplant recipients. 2001; 33: 1034-1035
(check this in PDF content)
24
Kliem V, Radermacher J, Hiss M et al. Conversion to tacrolimus for acute corticosteroid- and antibody-resistant rejection following kidney transplantation. Transplant Proc 1999; 31 [Suppl. 7A]: 37S-40S
(check this in PDF content)
25
Jordan ML, Shapiro R, Vivas et al. Outcome of tacrolimus conversion therapy for renal allograft rejection: 5-year follow­ up. Transplant Proc 1999; 31 [Suppl. 7A]: 81S-83S
(check this in PDF content)
26
Woodle ES, Thistlethwaite JR, Gordon JH et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection: a report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation 1996; 62: 594-599
(check this in PDF content)
27
Almond PS, Matas A, Gillingham K et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752-756
(check this in PDF content)
28
Pascual M, Theruvath T, Kawai T et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580-590
(check this in PDF content)
29
Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991;251:233-287
(check this in PDF content)
30
Pretagostini R, Rossi M, Colonnello M et al. Conversion from ciclosporin to tacrolimus in chronic allograft nephropathy. Transplant Proc 2001; 33: 1025-1026
(check this in PDF content)
31
Meier M, Nitschke M, Weidtmann B et al. Slowing the progression of chronic allograft nephropathy by conversion from cyclosporine to tacrolimus: a randomized controlled trial. Transplantation 2006; 81: 1035-40
(check this in PDF content)
32
Waid T for the CRAF Study Group. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure. Clin Transplant 2005; 19: 573-580
(check this in PDF content)
33
Morris-Stiff GJ, Baboolal K, Dunstan F, Jurewicz WA. Conversion from cyclosporin (Neoral) to tacrolimus (Prograf) in renal allograft recipients with chronic graft nephropathy: Results of an observational study. Transplant Int 1999; 12: 288-292
(check this in PDF content)
34
Shapiro R, Scantlebury VP, Jordan ML et al. FK-506 in pediatric kidney transplantation - Primary and rescue experience. Pediatr Nephrol 1995; 9: 43-48
(check this in PDF content)
35
Latta K, Offner G, Oldhafer K et al. Tacrolimus nach Nierentransplantation bei Kindern. Transplantationsmedizin 1994; [Suppl]: 19 (abstract)
(check this in PDF content)
36
Corey HE, Tellis V, Schechner R, Greenstein SM. Improved renal allograft survival in children treated with FK 506 (tacrolimus) rescue therapy. Pediatr Nephrol 1996; 10: 720-722
(check this in PDF content)
37
Flynn JT, Bunchman TE, Sherbotie JR. Indications, results, and complications of tacrolimus conversion in pediatric renal transplantation. Pediatr Transplant 2001; 5: 439-446
(check this in PDF content)
38
Shapiro R, Scantlebury VP, Jordan ML et al. FK506 in pediatric kidney transplantation - primary and rescue experience. Pediatr Nephrol 1995; 9: 43-48
(check this in PDF content)
39
Franz M, Regele H, Schmaldienst S et al. Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy? Transplantation 1998; 66: 1258-1262
(check this in PDF content)
40
Morris-Stiff G, Talbot D, Balaji V et al. Conversion of renal transplant recipients from cyclosporin (Neoral) to tacrolimus (Prograf) for haemolytic uraemic syndrome. Transplant Int 1998; 11 [Suppl. 1]: S98-S99
(check this in PDF content)
41
Zarifian A, Meleg-Smith S, O’Donovan R et al. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 1999; 55: 2457-2466
(check this in PDF content)
42
Lin CC, King KL, Chao YW et al. Tacrolimus-associated hemolytic uremic syndrome: a case analysis. J Nephrol 2003; 16: 580-585
(check this in PDF content)
43
Furlong T, Storb R, Anasetti C et al. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft- versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone M arrow Transplantation 2000; 26: 985-991
(check this in PDF content)
44
Busque S, Demers P, St-Louis G et al. Conversion from Neoral (cyclosporine) to tacrolimus of kidney transplant recipients for gingival hyperplasia or hypertrichosis. Transplant Proc 1998; 30: 1247-1248
(check this in PDF content)
45
Kohnle M, Lutkes P, Zimmermann U et al. Conversion from cyclosporine to tacrolimus in renal transplant recipients with gum hyperplasia. Transplant Proc 1999; 31 [Suppl. 7A]: 44S-45S
(check this in PDF content)
46
Margreiter R, Pohanka E, Sparacino V et al. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing cyclosporin- related side-effects. Transplant Int 2005; 18: 816-823
(check this in PDF content)
47
Plosker GL, Foster RH. Tacrolimus. A further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000; 59: 323-329
(check this in PDF content)
48
Artz MA, Boots JMM, Ligtenberg G et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4: 937-945
(check this in PDF content)
49
McCune TR, Thacker LR, Peters TG et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation. Transplantation 1998; 65: 87-92
(check this in PDF content)
50
Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001; 12: 368-373 Поступила в редакцию 26.10.2007 г.
(check this in PDF content)